A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...
Show More From the Division of Urology, Washington University School of Medicine, St. Louis, MO. Prostate cancer remains a significant public health problem. The current approach with ...
Prostate cancer screening slashes risk of dying from the disease by 13 per cent, major study reveals
Screening men for prostate cancer would save thousands of lives by slashing their risk of dying from the disease by 13 per cent, a major study reveals. Testing led to a ‘sustained reduction’ in deaths ...
There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...
Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916 No significant financial ...
The use of prostate-specific antigen (PSA) testing for prostate cancer screening remains the subject of scientific debate. Experts are unable to agree on how to balance the benefit of such testing ...
The European Randomized Study of Screening for Prostate Cancer (ERSPC) sheds new light on the long-term impact of ...
Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...
Prostate-specific antigen screening resulted in 13% lower prostate cancer mortality over a median 23 years of follow-up.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback